These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


110 related items for PubMed ID: 9462443

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Antipneumococcal activity of grepafloxacin compared to that of other agents by time-kill methodology.
    Pankuch GA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1998 May; 42(5):1263-5. PubMed ID: 9593163
    [Abstract] [Full Text] [Related]

  • 23. Comparative in-vitro activity of sparfloxacin and eight other antimicrobial agents against clinical isolates of non-tuberculous mycobacteria.
    Sánchez-Carrillo C, Cotarelo M, Cercenado E, Vicente T, Blázquez R, Bouza E.
    J Antimicrob Chemother; 1996 Jan; 37(1):151-4. PubMed ID: 8647757
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [In vitro activities of newly developed quinolones, fleroxacin, lomefloxacin and sparfloxacin against Mycobacterium tuberculosis].
    Kawahara S, Kamisaka K, Tada A, Nakada H, Mishima Y, Yoshimoto S, Matsuyama T, Kibata M, Nagare J.
    Kekkaku; 1991 Jun; 66(6):429-31. PubMed ID: 1942726
    [Abstract] [Full Text] [Related]

  • 26. [Prospects for development of new antituberculous drugs].
    Tomioka H.
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
    Harnett SJ, Fraise AP, Andrews JM, Jevons G, Brenwald NP, Wise R.
    J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.
    Hoogkamp-Korstanje JA, Dirks-Go SI, Kabel P, Manson WL, Stobberingh EE, Vreede RW, Davies BI.
    J Antimicrob Chemother; 1997 Mar; 39(3):411-4. PubMed ID: 9096192
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 6.